Please sign in to follow a disease.
Wanbangde Pharmaceutical Group Co., Ltd.
Clinical trials sponsored by Wanbangde Pharmaceutical Group Co., Ltd., explained in plain language.
A Chinese pharmaceutical company involved in drug development and manufacturing.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a Three-Pronged therapy reboot the brain after injury? Results expected Dec 2026 (estimated)
- Can a natural compound from moss help the brain? a new trial investigates Results expected Dec 2026 (estimated)
-
Can a natural compound slow Alzheimer's decline?
Disease control Recruiting nowThis trial is testing whether huperzine A, given as a controlled-release tablet, can improve thinking and daily living skills in people with mild-to-moderate Alzheimer's dementia. Participants will receive either huperzine A, a placebo, or an existing Alzheimer's drug (donepezil)…
Phase 2/3 • Sponsor: Wanbangde Pharmaceutical Group Co., LTD • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a Three-Pronged therapy reboot the brain after injury?
Disease control Recruiting nowThis trial explores whether combining two medications—ginkgo leaf dropping pills and huperzine A injection—with a non-invasive nerve stimulation therapy can improve cognitive function in adults who have lasting thinking and memory problems after a brain injury. Participants will …
Phase 4 • Sponsor: Wanbangde Pharmaceutical Group Co., LTD • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC